Compare Marathon Petroleum Corp (MPC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Marathon Petroleum Corp trades at $399.98 (market cap $111.70B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Marathon Petroleum Corp pays a 1.01% dividend while State Street SPDR S&P Biotech ETF pays none, and Marathon Petroleum Corp is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| MPC | XBI | |
|---|---|---|
Market Cap | $111.70B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $399.44 | $169.55 |
52-Week Low | $162.63 | $93.43 |
Enterprise Value | $138.23B | — |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today and near its 52-week high, with a bullish technical outlook from moving averages and strong momentum. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $17.73 surpassing the $14.27 forecast. Valuation ratios appear attractive with a P/E of 13.79 and P/S of 0.77, while profitability metrics like a 47.9% ROE highlight efficient capital use. Recent news emphasizes refinery investments and benefits from geopolitical energy risks.
The outlook for MPC is positive, driven by robust earnings performance, favorable refining margins, and strong analyst support with 26 buy ratings. Key opportunities include high-return projects and cash flow growth, with 2026 net income projected at $8.6B. Risks involve exposure to oil price volatility, cyclical demand, and rising debt-to-asset ratios, which increased to 42.59% in 2025. Investors should weigh solid fundamentals against sector-specific headwinds.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
